Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18347362 | 0.93 | NR1H4 (0.67) | NR1H4FXR2 | |
| SCHEMBL9960792 | 0.90 | NR1H4 (0.69) | NR1H4FXR2 | |
| SCHEMBL18843332 | 0.84 | NR1H4 (0.72) | NR1H4FXR2 | |
| SCHEMBL12188608 | 0.84 | NR1H4 (0.77) | NR1H4FXR2 | |
| SCHEMBL17079116 | 0.83 | NR1H4 (0.59) | NR1H4FXR2 | |
| SCHEMBL12168941 | 0.83 | NR1H4 (0.73) | NR1H4FXR2 | |
| SCHEMBL12808865 | 0.83 | NR1H4 (0.85) | NR1H4FXR2 | |
| SCHEMBL18347357 | 0.83 | NR1H4 (0.66) | NR1H4FXR2 | |
| SCHEMBL12168789 | 0.83 | NR1H4 (0.75) | NR1H4FXR2 | |
| SCHEMBL12168797 | 0.82 | NR1H4 (0.74) | NR1H4FXR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952042-B2 | FXR (NR1H4) binding and activity modulating compounds | PHENEX PHARMACEUTICALS AG (DE) | 2015-02-10 | — | — | US | claimed |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-09-13 | — | — | US | claimed |
| EP-2289883-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | Phenex Pharmaceuticals AG (DE) | 2011-03-02 | — | — | EP | claimed |
| US-10077268-B2 | FXR agonists and methods for making and using | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-09-18 | — | — | US | disclosed |
| EP-3267991-A1 | TREATING LATENT AUTOIMMUNE DIABETES OF ADULTS WITH FARNESOID X RECEPTOR AGONISTS TO ACTIVATE INTESTINAL RECEPTORS | Salk Institute for Biological Studies (US) | 2018-01-17 | — | — | EP | disclosed |
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-01-04 | — | — | US | disclosed |
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2017078928-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-05-11 | — | — | WO | disclosed |
| EP-3116878-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | Salk Institute for Biological Studies (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20160376279-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160376279-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-12-29 | — | — | US | disclosed |
| EP-2467366-B1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2014-11-12 | — | — | EP | disclosed |
| EP-2467366-B1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-09-13 | — | — | US | disclosed |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-09-13 | — | — | US | disclosed |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-09-13 | — | — | US | disclosed |
| EP-2467366-A1 | NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS | Phenex Pharmaceuticals AG (DE) | 2012-06-27 | — | — | EP | disclosed |
| EP-2289883-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | Phenex Pharmaceuticals AG (DE) | 2011-03-02 | — | — | EP | disclosed |
| WO-2011020615-A1 | NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011020615-A1 | NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | GLP1R, GIPR, FXR1 | NR1H4 10/4885FXR2 6/4885 |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885FXR2 5/4885 |
| US-10077268-B2 | FXR agonists and methods for making and using | NR1H4, FXR2, FXR1 | NR1H4 1/4885FXR2 2/4885 |
| US-20160376279-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | NR1H4, FXR2, FXR1 | NR1H4 1/4885FXR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.